EMAIL THIS PAGE TO A FRIEND

Cancer letters

The development of cisplatin resistance in neuroblastoma is accompanied by epithelial to mesenchymal transition in vitro.


PMID 25960282

Abstract

Neuroblastoma is a challenging childhood malignancy, with a very high percentage of patients relapsing following acquisition of drug resistance, thereby necessitating the identification of mechanisms of drug resistance as well as new biological targets contributing to the aggressive pathogenicity of the disease. In order to investigate the molecular pathways that are involved with drug resistance in neuroblastoma, we have developed and characterised cisplatin resistant sublines SK-N-ASCis24, KellyCis83 and CHP-212Cis100, integrating data of cell behaviour, cytotoxicity, genomic alterations and modulation of protein expression. All three cisplatin resistant cell lines demonstrated cross resistance to temozolomide, etoposide and irinotecan, all of which are drugs in re-initiation therapy. Array CGH analysis indicated that resistant lines have acquired additional genomic imbalances. Differentially expressed proteins were identified by mass spectrometry and classified by bioinformatics tools according to their molecular and cellular functions and their involvement into biological pathways. Significant changes in the expression of proteins involved with pathways such as actin cytoskeletal signalling (p = 9.28E-10), integrin linked kinase (ILK) signalling (p = 4.01E-8), epithelial adherens junctions signalling (p = 5.49E-8) and remodelling of epithelial adherens junctions (p = 5.87E-8) pointed towards a mesenchymal phenotype developed by cisplatin resistant SK-N-ASCis24. Western blotting and confocal microscopy of MYH9, ACTN4 and ROCK1 coupled with invasion assays provide evidence that elevated levels of MYH9 and ACTN4 and reduced levels of ROCK1 contribute to the increased ROCK1-independent migratory potential of SK-N-ASCis24. Therefore, our results suggest that epithelial-to-mesenchymal transition is a feature during the development of drug resistance in neuroblastoma.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

AV42203
Anti-ACTN4 (AB1) antibody produced in rabbit, affinity isolated antibody
AV42202
Anti-ACTN4 (AB2) antibody produced in rabbit, IgG fraction of antiserum
SAB2701841
Anti-actn4 antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
HPA001873
Anti-ACTN4 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB1408544
Anti-ACTN4 antibody produced in rabbit, purified immunoglobulin, buffered aqueous solution
AV100657
Anti-AREB6 antibody produced in rabbit, affinity isolated antibody
HPA001644
Anti-MYH9 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB2101542
Anti-MYH9 antibody produced in rabbit, affinity isolated antibody
SAB1305939
ANTI-MYL12B (N-TERM) antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
SAB1100284
Anti-SNAI1 (21-35) antibody produced in rabbit, IgG fraction of antiserum, buffered aqueous solution
SAB2501370 Anti-SNAI1 (N-terminal) antibody produced in goat, affinity isolated antibody, buffered aqueous solution
SAB1406456
Anti-SNAI1 antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
AV33314
Anti-SNAI1 antibody produced in rabbit, affinity isolated antibody
SAB4502825
Anti-SNAI1, C-Terminal antibody produced in rabbit, affinity isolated antibody
SAB1306281
ANTI-SNAIL (N-TERM D24) antibody produced in rabbit, IgG fraction of antiserum, buffered aqueous solution
SAB1305974
ANTI-SNAIL (N-TERM R8) antibody produced in rabbit, purified immunoglobulin, buffered aqueous solution
SAB2102759
Anti-ZEB1 antibody produced in rabbit, affinity isolated antibody
SAB3500514
Anti-ZEB1 antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
WH0000081M1
Monoclonal Anti-ACTN4 antibody produced in mouse, clone 4D10, purified immunoglobulin, buffered aqueous solution
SAB1403521
Monoclonal Anti-ACTN4 antibody produced in mouse, clone 4D10, ascites fluid
SAB1403431
Monoclonal Anti-MRLC2, (C-terminal) antibody produced in mouse, clone 1B22, purified immunoglobulin, buffered aqueous solution
WH0004627M3
Monoclonal Anti-MYH9 antibody produced in mouse, clone 2B3, purified immunoglobulin, buffered aqueous solution
SAB1404102
Monoclonal Anti-MYH9 antibody produced in mouse, clone 3C7, purified immunoglobulin, buffered aqueous solution
SAB1409335
Monoclonal Anti-MYH9 antibody produced in mouse, clone 4D1, purified immunoglobulin, buffered aqueous solution
SAB1401367 Monoclonal Anti-SNAI1 antibody produced in mouse, clone 1A5, purified immunoglobulin, buffered aqueous solution
SAB1404386
Monoclonal Anti-SNAI1 antibody produced in mouse, clone 2G11, purified immunoglobulin, buffered aqueous solution
SAB5300373
Monoclonal Anti-SNAI1 antibody produced in mouse, clone 6D2, ascites fluid
WH0006935M1
Monoclonal Anti-TCF8 antibody produced in mouse, clone 4C4, purified immunoglobulin, buffered aqueous solution
AMAB90510
Monoclonal Anti-ZEB1 antibody produced in mouse, Prestige Antibodies® Powered by Atlas Antibodies, clone CL0151, purified immunoglobulin, buffered aqueous glycerol solution